TrialJournal of virology2002

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy.

Xia Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.